Showing 6591-6600 of 9119 results for "".
- Dermatologists Can Spot Early Psoriatic Arthritishttps://practicaldermatology.com/news/20120521-dermatologists_can_spot_early_psoriatic_arthritis/2459795/Clinical dermatologists could help diagnose early psoriatic arthritis (EPsA) through the use of patient questioning and subsequent imaging studies in collaboration with rheumatologists and radiologists, data suggest. (
- New School Initiative for Skin Cancer Preventionhttps://practicaldermatology.com/news/20120515-new_school_initiative_for_skin_cancer_prevention/2459798/La Roche-Posay recently collaborated with the Women's Dermatologic Society to launch “Time Out, Protect Your Skin” (TOPS) in schools to educate children and families about skin cancer prevention. New York City's Grace Church School was the first s
- La Roche-Posay Awards Two Researchershttps://practicaldermatology.com/news/20120514-la_roche-posay_awards_two_researchers/2459803/At its seventh annual North American Foundation Research Awards, La Roche-Posay honored winners Sarina B. Elmariah, MD, PhD and Marie S. Tuttle, MD. Both researchers received a $10,000 grant to continue dermatological research and were honored at t
- Provectus Pharmaceuticals' PV-10 Phase 2 Final Data To Be Presentedhttps://practicaldermatology.com/news/20120509-provectus_pharmaceuticals_pv-10_phase_2_final_data_to_be_presented/2459806/Phase 2 final data on PV-10 for metastatic melanoma by Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) will be presented at the second European PostASCO Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanom
- Novartis Acquires Fougera Pharma for $1.5 Billionhttps://practicaldermatology.com/news/20120504-novartis_acquires_fougera_pharma_for_15_billion/2459809/With it's $1.5 billion acquisition of US-based Fougera Pharmaceuticals, Novartis will be the biggest maker of dermatologic generics in the country. The Fougera products will add to those of Novartis's existing generics unit Sandoz.
- Mylan, Impax Win Ruling in Doryx Generics Patent Casehttps://practicaldermatology.com/news/20120502-mylan_impax_win_ruling_in_doryx_generics_patent_case/2459810/Mylan Inc. (MYL) said it began selling a generic version of the antibiotic Doryx today after a judge ruled it didn't infringe a patent held by Warner Chilcott (WCRX) Plc.
- PhotoMedex Completes Sale of Common Stock for $40 Millionhttps://practicaldermatology.com/news/20120430-photomedex_completes_sale_of_common_stock_for_40_million/2459812/PhotoMedex, Inc. (NasdaqGS: PHMD) expects gross proceeds of $40 million, before deducting underwriting discounts, commissions and other offering expenses, from recent sale of shares of common stock. The company closed concurrent registered offerin
- PreCision Dermatology Acquires Assets of Triax Pharmaceuticalshttps://practicaldermatology.com/news/20120430-precision_dermatology_acquires_assets_of_triax_pharmaceuticals/2459813/PreCision Dermatology has acquired the assets of Triax Pharmaceuticals LLC, a specialty pharmaceutical company with products including the mid-potency topical steroid Locoid, as well as Minocin and Tretin-X. Onset Dermatologics, the prescrip
- Promiseb Complete Launches for Seborrheic Dermatitishttps://practicaldermatology.com/news/20120425-promiseb_complete_launches_for_seborrheic_dermatitis/2459814/Promiseb Complete, a new regimen for patients with seborrheic dermatitis (SD), is now available from Promius Pharma, LLC, an affiliate of Dr. Reddy's Laboratories,. The line features Promiseb Topical Cream, a non-steroidal, prescription cream fo
- Enrollments Complete for Two Phase 2 ALA-PDT AK Trialshttps://practicaldermatology.com/news/20120424-enrollments_complete_for_two_phase_2_ala-pdt_ak_trials/2459815/DUSA Pharmaceuticals (NASDAQ GM: DUSA) completed patient enrollment in its Phase 2 clinical trial studying the broad area application with 1-, 2-, and 3-hour drug incubation for the treatment of actinic keratoses (AKs) of the face or scalp